The study by Agarwal and Joshi 1 reports the effectiveness of amitriptyline and lamotrigine in neuropathic pain after traumatic spinal cord injuries. Current available evidence, as demonstrated in a recently published guideline for management of neuropathic pain in spinal cord injury, 2 is scarce regarding comparison of two different drugs, as they focus on placebo controlled trials. Amitriptyline was compared to gabapentin and diphenhydramine as an active placebo on a small trial. 3 Lamotrigine was only compared to placebo, and demonstrated to be effective in patients with incomplete lesion just after a post hoc analysis. 4 Although Agarwal's trial sums to this body of evidence, the clinical information that can be extracted is uncertain. The Shortform MCGill Pain Questionnaire-2, chosen as a neuropathic pain measurement, has a good interobserver correlation, but until now a minimal clinically important difference has not been established. 5 The authors did not clearly report which of the outcomes was considered to be the primary outcome, and they also didn't report study power (neither pre-determined nor post hoc) for the outcomes assessed. Since the study is categorized as randomized, it would be of great interest to have patient characteristics and their distribution in both the amitriptyline and lamotrigine treatment groups available in the article. 6 Unfortunately, spinal cord-related neuropathic pain treatment still lacks a strong body of evidence. This is an interesting study with a direct comparison of two drugs. Addressing these issues would be helpful for a better understanding of the reported results. Also, in times of systematic reviews, it would be interesting to have these questions answered.
